deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02239120

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)

Sponsor: Boehringer Ingelheim

Conditions Secondary Prevention Stroke
Interventions ASA 100 mg dabigatran etexilate optional ASA as comedication placebo to ASA placebo to dabigatran etexilate placebo to optional ASA as comedication
Updated 24 times since 2017 Last updated: Aug 13, 2019 Started: Nov 27, 2014 Primary completion: Aug 14, 2018 Completion: Aug 14, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Secondary Prevention and Stroke, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 24 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Aug 2019 · 10 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – present · 8 months · monthly snapshot

Change History

24 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Nov 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

▶ Show 19 earlier versions

  1. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  2. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE3

  3. Aug 2019 — Oct 2019 [monthly]

    Completed PHASE3

  4. Oct 2018 — Aug 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Jul 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  8. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE3

  9. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  10. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  11. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  12. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  13. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  14. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  15. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  16. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

  17. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  18. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  19. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Aarau, Switzerland , Adelaide, Australia , Ahtme, Estonia , Aichi, Nagoya, Japan , Aichi, Toyohashi, Japan , Aichi, Toyota, Japan , Aix-en-Provence, France , Akita, Akita, Japan , Albacete, Spain and 436 more locations